Progress in acute myeloid leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 3, 2015, Pages 139-151

  Kadia, Tapan M ^a   Ravandi, Farhad ^a   O'Brien, Susan ^a   Cortes, Jorge ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

AML; Review; Targeted therapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARAC PROTEIN; CD135 ANTIGEN; NUCLEOPHOSMIN; NUCLEOSIDE ANALOG; NUCLEAR PROTEIN; VASCULOTROPIN RECEPTOR 1;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; GENE MUTATION; HUMAN; KARYOTYPE; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGE; ALLOTRANSPLANTATION; CHROMOSOME ABERRATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MUTATION; TREATMENT OUTCOME;

ABNORMAL KARYOTYPE; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84923574693     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.08.006     Document Type: Review

References (135)

1. H. Dohner, E.H. Estey, and S. Amadori Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 115 2010 453 474
2. D. Grimwade, R.K. Hills, and A.V. Moorman Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials Blood 116 2010 354 365
3. J.C. Byrd, K. Mrozek, and R.K. Dodge Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood 100 2002 4325 4336
4. C.D. Bloomfield, D. Lawrence, and J.C. Byrd Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res 58 1998 4173 4179
5. Borthakur G, Cortes JE, O'Brien SM, et al. Effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on relapse-free survival in patients with newly diagnosed core-binding factor acute myelogenous leukemia. ASCO Meeting Abstracts 2012; 30:6528.
6. J.C. Byrd, R.K. Dodge, and A. Carroll Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered J Clin Oncol 17 1999 3767 3775
7. J.C. Byrd, A.S. Ruppert, and K. Mrozek Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461 J Clin Oncol 22 2004 1087 1094
8. A.K. Burnett, R.K. Hills, and D. Milligan Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial J Clin Oncol 9 2011 369 377
9. K.F. Bradstock, J.P. Matthews, and R.M. Lowenthal A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine Blood 105 2005 481 488
10. G. Borthakur, H. Kantarjian, and X. Wang Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival Cancer 113 2008 3181 3185
11. A. Burnett, R.K. Hills, and N. Russell Reasons for survival improvement in core binding factor AML: a 25-year analysis of the UK MRC/NCRI AML trials Blood 122 2013 358
12. S.H. Petersdorf, K.J. Kopecky, and M. Slovak A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia Blood 121 2013 4854 4860
13. R.K. Hills, S. Petersdorf, and E.H. Estey The addition of gemtuzumab ozogamicin (GO) to induction chemotherapy reduces relapse and improves survival in patients without adverse risk karyotype: results of an individual patient meta-analysis of the five randomised trials Blood 122 2013 356
14. R. Cairoli, A. Beghini, and G. Grillo Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study Blood 107 2006 3463 3468
15. S.H. Park, H.S. Chi, and S.K. Min Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia Leuk Res 35 2011 1376 1383
16. P. Paschka, G. Marcucci, and A.S. Ruppert Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study J Clin Oncol 24 2006 3904 3911
17. S. Schnittger, T.M. Kohl, and T. Haferlach KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival Blood 107 2006 1791 1799
18. J.A. Yin, M.A. O'Brien, and R.K. Hills Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial Blood 120 2012 2826 2835
19. G. Marcucci, S. Geyer, and J. Zhao Adding the KIT inhibitor dasatinib (DAS) to standard induction and consolidation therapy for newly diagnosed patients (pts) with core binding factor (CBF) acute myeloid leukemia (AML): initial results of the CALGB 10801 (Alliance) study Blood 122 2013 357
20. G. Borthakur, J.E. Cortes, and F. Ravandi Replacing gemtuzumab ozogamicin with idarubicin in frontline fludarabine, cytarabine and G-CSF based regimen does not compromise outcome in core binding factor acute myelogenous leukemia Blood 122 2013 3971
21. J.V. Raelson, C. Nervi, and A. Rosenauer The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells Blood 88 1996 2826 2832
22. Z.Y. Wang, and Z. Chen Acute promyelocytic leukemia: from highly fatal to highly curable Blood 111 2008 2505 2515
23. V. Mathews, B. George, and K.M. Lakshmi Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity Blood 107 2006 2627 2632
24. C. Niu, H. Yan, and T. Yu Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients Blood 94 1999 3315 3324
25. Z.X. Shen, G.Q. Chen, and J.H. Ni Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients Blood 89 1997 3354 3360
26. Z.X. Shen, Z.Z. Shi, and J. Fang All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia Proc Natl Acad Sci U S A 101 2004 5328 5335
27. S.L. Soignet, S.R. Frankel, and D. Douer United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia J Clin Oncol 19 2001 3852 3860
28. S.L. Soignet, P. Maslak, and Z.G. Wang Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide N Engl J Med 339 1998 1341 1348
29. A. Ghavamzadeh, K. Alimoghaddam, and S. Rostami Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia J Clin Oncol 29 2011 2753 2757
30. Y. Jing, L. Wang, and L. Xia Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo Blood 97 2001 264 269
31. E. Estey, G. Garcia-Manero, and A. Ferrajoli Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia Blood 107 2006 3469 3473
32. F. Ravandi, E. Estey, and D. Jones Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin J Clin Oncol 27 2009 504 510
33. F. Lo-Coco, G. Avvisati, and M. Vignetti Retinoic acid and arsenic trioxide for acute promyelocytic leukemia N Engl J Med 369 2013 111 121
34. S. Frohling, R.F. Schlenk, and J. Breitruck Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm Blood 100 2002 4372 4380
35. P.D. Kottaridis, R.E. Gale, and M.E. Frew The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 2001 1752 1759
36. R.F. Schlenk, K. Dohner, and J. Krauter Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1909 1918
37. C. Thiede, C. Steudel, and B. Mohr Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 2002 4326 4335
38. M. Yanada, K. Matsuo, and T. Suzuki Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis Leukemia 19 2005 1345 1349
39. C.C. Smith, Q. Wang, and C.S. Chin Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia Nature 485 2012 260 263
40. S.P. Whitman, A.S. Ruppert, and M.D. Radmacher FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications Blood 111 2008 1552 1559
41. A.S. Moore, A. Faisal, and D. Gonzalez de Castro Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns Leukemia 26 2012 1462 1470
42. R.E. Gale, C. Green, and C. Allen The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia Blood 111 2008 2776 2784
43. J. How, J. Sykes, and V. Gupta Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia Cancer 118 2012 6110 6117
44. K.W. Pratz, T. Sato, and K.M. Murphy FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML Blood 115 2010 1425 1432
45. M. Levis, R. Pham, and B.D. Smith In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects Blood 104 2004 1145 1150
46. F. Ravandi, J.E. Cortes, and D. Jones Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia J Clin Oncol 28 2010 1856 1862
47. F. Ravandi, C. Arana Yi, and J.E. Cortes Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia Leukemia 28 2014 1543 1545
48. R.M. Stone, T. Fischer, and R. Paquette Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia Leukemia 26 2012 2061 2068
49. Rollig C, Muller-Tidow C, Huttmann A, et al. Sorafenib versus placebo in addition to standard therapy in adult patients >=60 years with newly diagnosed acute myeloid leukemia: results from the randomized-controlled soraml trial. ASH Annual Meeting Abstracts 2012; 120:144.
50. H. Serve, U. Krug, and R. Wagner Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial J Clin Oncol 31 2013 3110 3118
51. M. Levis FLT3/ITD AML and the law of unintended consequences Blood 117 2011 6987 6990
52. T. Sato, X. Yang, and S. Knapper FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo Blood 117 2011 3286 3293
53. F. Ravandi, M.L. Alattar, and M.R. Grunwald Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation Blood 121 2013 4655 4662
54. Cortes JE, Perl AE, Dombret H, et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients >= 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. ASH Annual Meeting Abstracts 2012; 120:48.
55. K. Dohner, R.F. Schlenk, and M. Habdank Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations Blood 106 2005 3740 3746
56. S. Schnittger, C. Schoch, and W. Kern Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype Blood 106 2005 3733 3739
57. C. Thiede, S. Koch, and E. Creutzig Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) Blood 107 2006 4011 4020
58. R.G. Verhaak, C.S. Goudswaard, and W. van Putten Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance Blood 106 2005 3747 3754
59. J.W. Vardiman, J. Thiele, and D.A. Arber The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951
60. H. Kantarjian, S. O'Brien, and J. Cortes Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome Cancer 106 2006 1090 1098
61. H. Kantarjian, F. Ravandi, and S. O'Brien Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia Blood 116 2010 4422 4429
62. R.J. Mayer, R.B. Davis, and C.A. Schiffer Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B N Engl J Med 331 1994 896 903
63. H.F. Fernandez, Z. Sun, and X. Yao Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 2009 1249 1259
64. J.K. Weick, K.J. Kopecky, and F.R. Appelbaum A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study Blood 88 1996 2841 2851
65. J.F. Bishop, J.P. Matthews, and G.A. Young A randomized study of high-dose cytarabine in induction in acute myeloid leukemia Blood 87 1996 1710 1717
66. W. Kern, and E.H. Estey High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials Cancer 107 2006 116 124
67. B. Lowenberg, T. Pabst, and E. Vellenga Cytarabine dose for acute myeloid leukemia N Engl J Med 364 2011 1027 1036
68. R. Willemze, S. Suciu, and G. Meloni High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial J Clin Oncol 32 2014 219 228
69. A.K. Burnett, N.H. Russell, and R.K. Hills Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial J Clin Oncol 31 2013 3360 3368
70. W. Plunkett, J.O. Liliemark, and T.M. Adams Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy Cancer Res 47 1987 3005 3011
71. W. Plunkett, J.O. Liliemark, and E. Estey Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C Semin Oncol 14 1987 159 166
72. Y. Park, D.S. Kim, and S.Y. Lee High-dose cytarabine consolidation (≥1.5 g/m2) might have shown a better outcomes than intermediate-dose cytarabine (1.0 g/m2) combined with anthracyclines in AML patients who had achieved complete remissions in the first induction by standard 3+7 regimen Blood 122 2013 2692
73. B. Lowenberg Sense and nonsense of high-dose cytarabine for acute myeloid leukemia Blood 121 2013 26 28
74. V. Gandhi, E. Estey, and M.J. Keating Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions Blood 87 1996 256 264
75. V. Gandhi, E. Estey, and M.J. Keating Biochemical modulation of arabinosylcytosine for therapy of leukemias Leuk Lymphoma 10 suppl 1993 109 114
76. V. Gandhi, E. Estey, and M.J. Keating Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy J Clin Oncol 11 1993 116 124
77. E.H. Estey, P.F. Thall, and S. Pierce Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome Blood 93 1999 2478 2484
78. J. Holowiecki, S. Grosicki, and T. Robak Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study Leukemia 18 2004 989 997
79. J. Holowiecki, S. Grosicki, and S. Giebel Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study J Clin Oncol 30 2012 2441 2448
80. A. Nazha, H. Kantarjian, and F. Ravandi Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients
81. B. Lowenberg, G.J. Ossenkoppele, and W. van Putten High-dose daunorubicin in older patients with acute myeloid leukemia N Engl J Med 361 2009 1235 1248
82. 2 results in similar complete response rate, relapse-free and overall survival Blood 122 2013 66
83. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group Br J Haematol 103 1998 100 109
84. C. Pautas, F. Merabet, and X. Thomas Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study J Clin Oncol 28 2010 808 814
85. C. Gardin, S. Chevret, and C. Pautas Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older J Clin Oncol 31 2013 321 327
86. F. Mandelli, M. Vignetti, and S. Suciu Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10 J Clin Oncol 27 2009 5397 5403
87. A.K. Burnett, D. Milligan, and A.G. Prentice A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment Cancer 109 2007 1114 1124
88. H. Tilly, S. Castaigne, and D. Bordessoule Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly J Clin Oncol 8 1990 272 279
89. H.K. Al-Ali, N. Jaekel, and C. Junghanss Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study Leuk Lymphoma 53 2012 110 117
90. L. Maurillo, A. Venditti, and A. Spagnoli Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program Cancer 118 2012 1014 1022
91. N. Sudan, J.M. Rossetti, and R.K. Shadduck Treatment of acute myelogenous leukemia with outpatient azacitidine Cancer 107 2006 1839 1843
92. L.R. Silverman, D.R. McKenzie, and B.L. Peterson Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B J Clin Oncol 24 2006 3895 3903
93. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia J Clin Oncol 28 2010 562 569
94. P. Font Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia Adv Ther 28 suppl 3 2011 1 9
95. A.F. Cashen, G.J. Schiller, and M.R. O'Donnell Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia J Clin Oncol 28 2010 556 561
96. H.M. Kantarjian, X.G. Thomas, and A. Dmoszynska Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia J Clin Oncol 30 2012 2670 2677
97. A. Quintas-Cardama, F. Ravandi, and T. Liu-Dumlao Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia Blood 120 2012 4840 4845
98. W. Blum, R. Garzon, and R.B. Klisovic Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine Proc Natl Acad Sci U S A 107 2010 7473 7478
99. E.K. Ritchie, E.J. Feldman, and P.J. Christos Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia Leuk Lymphoma 54 2013 2003 2007
100. S. Faderl, F. Ravandi, and X. Huang Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients Cancer 118 2012 4471 4477
101. T.M. Kadia, J.E. Cortes, and G. Borthakur Phase II trial of cladribine and low-dose araC alternating with decitabine in older patients with AML J Clin Oncol 32 2014 5
102. H. Kantarjian, E. Jabbour, and K. Yee First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML) Blood 122 2013 497
103. J.E. Lancet, J.E. Cortes, and D.E. Hogge Phase II, multicenter, randomized, open label trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients with untreated AML 60-75 years of age Blood 123 2014 3239 3246
104. G. Juliusson, P. Antunovic, and A. Derolf Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Blood 113 2009 4179 4187
105. M.A. Sekeres, P. Elson, and M.E. Kalaycio Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients Blood 113 2009 28 36
106. S. Bertoli, E. Berard, and F. Huguet Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia Blood 121 2013 2618 2626
107. A.K. Burnett, K. Wheatley, and A.H. Goldstone The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial Br J Haematol 118 2002 385 400
108. P.A. Cassileth, D.P. Harrington, and F.R. Appelbaum Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission N Engl J Med 339 1998 1649 1656
109. J.J. Cornelissen, W.L. van Putten, and L.F. Verdonck Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109 2007 3658 3666
110. J.L. Harousseau, J.Y. Cahn, and B. Pignon Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM) Blood 90 1997 2978 2986
111. R.A. Zittoun, F. Mandelli, and R. Willemze Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups N Engl J Med 332 1995 217 223
112. M.L. Slovak, K.J. Kopecky, and P.A. Cassileth Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 96 2000 4075 4083
113. J. Koreth, R. Schlenk, and K.J. Kopecky Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials JAMA 301 2009 2349 2361
114. Q. Bashir, B.S. Andersson, and M. Fernandez-Vina Unrelated donor transplantation for acute myelogenous leukemia in first remission Biol Blood Marrow Transplant 17 2011 1067 1071
115. H.M. Lazarus, W.S. Perez, and J.P. Klein Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research Br J Haematol 132 2006 755 769
116. J. Sierra, B. Storer, and J.A. Hansen Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience Bone Marrow Transplant 26 2000 397 404
117. I. Yakoub-Agha, F. Mesnil, and M. Kuentz Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy J Clin Oncol 24 2006 5695 5702
118. Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia N Engl J Med 368 2013 2059 2074
119. T.J. Ley, L. Ding, and M.J. Walter DNMT3A mutations in acute myeloid leukemia N Engl J Med 363 2010 2424 2433
120. F. Thol, F. Damm, and A. Ludeking Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia J Clin Oncol 29 2011 2889 2896
121. N. Boissel, O. Nibourel, and A. Renneville Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group J Clin Oncol 28 2010 3717 3723
122. C.L. Green, C.M. Evans, and R.K. Hills The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status Blood 116 2010 2779 2782
123. G. Marcucci, K. Maharry, and Y.Z. Wu IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study J Clin Oncol 28 2010 2348 2355
124. P. Paschka, R.F. Schlenk, and V.I. Gaidzik IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication J Clin Oncol 28 2010 3636 3643
125. F. Ravandi, K. Patel, and R. Luthra Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin Cancer 118 2012 2665 2673
126. S. Schnittger, C. Haferlach, and M. Ulke IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status Blood 116 2010 5486 5496
127. F. Thol, F. Damm, and K. Wagner Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia Blood 116 2010 614 616
128. K. Wagner, F. Damm, and G. Gohring Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor J Clin Oncol 28 2010 2356 2364
129. P.S. Ward, J. Patel, and D.R. Wise The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate Cancer Cell 17 2010 225 234
130. L. Sellner, D. Capper, and J. Meyer Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations Eur J Haematol 85 2010 457 459
131. M.E. Tueroa, O. Abdel-Wahab, and C. Lu Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 2010 553 567
132. Stein E, Tallman MS, Pollyea D, et al. Clinical safety and activity in a phase I trial AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies. AACR Annual Meeting 2014, Abstract CT103.
133. T.M. Kadia, H. Kantarjian, and S. Kornblau Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS Cancer 118 2012 5550 5559
134. A. Neubauer, K. Maharry, and K. Mrozek Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study J Clin Oncol 26 2008 4603 4609
135. Borthakur G, Popplewell L, Boyiadzis M, et al. Phase I/II trial of the MEK1/2 inhibitor trametinib (GSK1120212) in relapsed/refractory myeloid malignancies: evidence of activity in patients with RAS mutation-positive disease. ASH Annual Meeting Abstracts 2012; 120:677.